{"id":57305,"date":"2012-11-10T22:01:44","date_gmt":"2012-11-10T22:01:44","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/pluristem-shares-bounce-back-after-thursday-plunge.php"},"modified":"2012-11-10T22:01:44","modified_gmt":"2012-11-10T22:01:44","slug":"pluristem-shares-bounce-back-after-thursday-plunge","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/pluristem-shares-bounce-back-after-thursday-plunge.php","title":{"rendered":"Pluristem shares bounce back after Thursday plunge"},"content":{"rendered":"<p><p>    NEW YORK (AP)  Shares of biotechnology company Pluristem Therapeutics    Inc. bounced back Friday after the company responded to    a report that a patient treated with its PLX stem cell therapy    had died.  <\/p>\n<p>    THE SPARK: Bloomberg BusinessWeek reported    Thursday that Pluristem did not disclose the death    of a young patient who had been treated with its placental    cell    therapy before a $32 million public stock sale in September.    Shares of Pluristem fell 23 percent Thursday.  <\/p>\n<p>    The Israeli    company said Thursday evening that parts of the article    were inaccurate or misleading. It said the patient, a Romanian    girl whose name has not been disclosed, was \"in imminent danger    of death\" at the time she was treated with the stem cells. She    was not part of an organized clinical trial and was treated on    a compassionate basis because no therapy options remained.  <\/p>\n<p>    Pluristem said the patient lived for six months after her    treatment. She returned to Romania four months before she died    and the company was not monitoring her health. Pluristem said    it was not aware of her death at the time it sold the    additional stock. Bloomberg said the patient died Sept. 12, the    day the stock sale was announced. The sale closed a week later.  <\/p>\n<p>    \"The formal report relating to the death clearly stated that    there was no connection between the PLX cell treatment and the    death of the patient,\" Pluristem said in a press release.  <\/p>\n<p>    THE BIG PICTURE: Pluristem said that three patients have been    treated with PLX on a compassionate basis  including the    Romanian girl  and two have died. The company said it believes    the patients lived longer than expected following treatment,    which demonstrates that PLX therapy can be effective. The    company is studying the stem cells as a treatment for    peripheral artery disease, nerve pain, and other conditions.  <\/p>\n<p>    THE STOCK: Shares of Pluristem rose 39 cents, or 13.7 percent,    to $3.24 on Friday. The stock reached an annual high of $5 per    share in August, and including Friday's gains, the shares are    down 29 percent since the company announced the stock offering.  <\/p>\n<\/p>\n<p>Continue reading here:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/news.yahoo.com\/pluristem-shares-bounce-back-thursday-plunge-230416031--finance.html;_ylt=A2KJjb2tzp5QcEEAGab_wgt.\" title=\"Pluristem shares bounce back after Thursday plunge\">Pluristem shares bounce back after Thursday plunge<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> NEW YORK (AP) Shares of biotechnology company Pluristem Therapeutics Inc. bounced back Friday after the company responded to a report that a patient treated with its PLX stem cell therapy had died.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/pluristem-shares-bounce-back-after-thursday-plunge.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[25],"tags":[],"class_list":["post-57305","post","type-post","status-publish","format-standard","hentry","category-stem-cell-therapy"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/57305"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=57305"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/57305\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=57305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=57305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=57305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}